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Abstract
Background: Previously we have generated the monoclonal antibody SM5-1 by using a subtractive
immunization protocol of human melanoma. This antibody exhibits a high sensitivity for primary
melanomas of 99% (248/250 tested) and for metastatic melanoma of 96% (146/151 tested) in
paraffin embedded sections. This reactivity is superior to the one obtained by HMB-45, anti-MelanA
or anti-Tyrosinase and is comparable to anti-S100. However, as compared to anti-S100, the
antibody SM5-1 is highly specific for melanocytic lesions since 40 different neoplasms were found
to be negative for SM5-1 by immunohistochemistry. The antigen recognized by SM5-1 is unknown.
Methods: In order to characterize the antigen recognized by mAb SM5-1, a cDNA library was
constructed from the metastatic human melanoma cell line SMMUpos in the Uni-ZAP lambda phage
and screened by mAb SM5-1. The cDNA clones identified by this approach were then sequenced
and subsequently analyzed.
Results:  Sequence analysis of nine independent overlapping clones (length 3100–5600 bp)
represent fibronectin cDNA including the ED-A, but not the ED-B region which are produced by
alternative splicing. The 89aa splicing variant of the IIICS region was found in 8/9 clones and the
120aa splicing variant in 1/9 clones, both of which are included in the CS1 region of fibronectin
being involved in melanoma cell adhesion and spreading.
Conclusion: The molecule recognized by SM5-1 is a melanoma associated FN variant expressed
by virtually all primary and metastatic melanomas and may play an important role in melanoma
formation and progression. This antibody is therefore not only of value in immunohistochemistry,
but potentially also for diagnostic imaging and immunotherapy.
Background
Melanoma-associated antigens such as MelanA/Mart-1 or
tyrosinase recognized by monoclonal antibodies can be
used as diagnostic markers for immunohistochemistry or
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as therapeutic targets for specific immunotherapy. Previ-
ously we have produced a panel of monoclonal antibod-
ies (mAb) by subtractive immunization of the human
melanoma cell line SMMUneg, generated from a primary
melanoma and the SMMUpos cell line, generated from
the same patient's metastatic melanoma [1]. One of the
antibodies, mAb SM5-1 was found to react with SMMU-
pos, but not with SMMUneg, being suggestive for the rec-
ognition of a metastases associated molecule. Upon
detailed screening we found that SM5-1 and HMB-45 had
a comparable sensitivity of 97% to 99% in detecting par-
affin embedded primary melanomas, but SM5-1 was
superior to HMB-45 in detecting metastases (146/151,
96% vs. 126/151, 83%). SM5-1 was shown to be highly
specific for melanocytic lesions with negative staining of
40 different non-melanocytic neoplasms [2]. Moreover,
when we compared the immunohistochemical staining
pattern of SM5-1 with that of anti-MART-1 (mAb A103)
and anti-tyrosinase (mAb T311) we found an overall reac-
tivity of 92% (318/344) for SM5-1, 83% (285/344) for
MART-1 and 71% (245/344) for tyrosinase in primary
and metastatic melanoma specimens. 52 of 56 MART-1-
negative and 81 of 89 tyrosinase-negative metastases were
positive for SM5-1 [3]. Therefore, mAb SM5-1 is of high
value in immunohistochemistry of melanoma, though
the antigen recognized by SM5-1 is unknown. The differ-
ential screening of a cDNA library constructed from meta-
static and non-metastatic variants is used to identify novel
genes possibly associated with the progress of melanoma
[4,5]. Some genes identified by cDNA screening were
either higher or lower expressed in the metastatic counter-
part than in the primary one [6]. In the presented study, a
FACS analyses with SM5-1 and Fibronectin antibodies Figure 1
FACS analyses with SM5-1 and Fibronectin antibodies. SMMUpos cells react with mAb SM5-1 and the fibronectin 
mAbs TV-15 and FN15 while SMMUneg cells are negative for all mAbs.
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SMMUpos SMMUneg
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cDNA library of SMMUpos cells was constructed into the
Uni-ZAP lambda phage system and screened with SM5-1
in order to identify the antigen recognized by SM5-1.
Methods
Cell lines and antibodies
The human melanoma cell lines SMMUpos and
SMMUneg were established from the primary and meta-
static lesion, respectively, of the same patient and were
cultured in RPMI 1640 (GibcoBRL), supplemented with
10% FCS (GibcoBRL), 2 mM L-Glutamine (GibcoBRL),
50 I.U./ml penicillin (Sigma) and 50 ug/ml streptomycin
(Sigma) at 37°C, 5% CO2 in a humidified incubator. The
47 other melanoma cell lines were generated from meta-
static lesions of melanoma patients and were treated and
kept identical as the SMMU cell lines. Informed consent
was obtained from all patients prior to tissue sampling.
The mAb SM5-1 (mouse IgG1) was generated as previ-
ously described. The Fibronectin mAbs TV-1 (Dianova,
Hamburg, Germany) and FN-15 (ICN Biomedicals, OH,
USA) are both mouse IgG1 antibodies and were used at a
dilution of 1:100 or 1:200, respectively. FITC-conjugated
goat anti-mouse IgG1 (Dianova) was used as controls at
1:10.
Flow cytometry and cytospins
The cell monolayer were harvested by a brief exposure to
0.05% trypsin/0.02% EDTA in PBS (GibcoBRL), resus-
pended in PBS and washed twice and resuspended in the
staining buffer (10% inactivated FCS/0.1% sodium azide
in PBS, Sigma) containing 10 ug/ml of mAb SM5-1 or
mouse IgG1 (Sigma) as negative control. After 30 minutes
at 4°C incubation, cells were washed and resuspended in
the staining buffer containing FITC labeled goat anti-
mouse IgG1, incubated for 30 minutes at 4°C and ana-
lyzed with a flow cytometer (FacsCalibur, Becton Dickin-
son). For staining cytospins the cells were washed and
suspended on a glass microscope slide, followed by cen-
trifugation for 4 minutes at 400 rpm in a Shandon Cyt-
ospin 2 (Shandon, Germany). The slides were fixed in
acetone and stained with a two antibodies/streptavidin-
biotin (LSAB) method (DAKO). Slides were incubated
with 10 ug/ml SM5-1 antibody or mouse IgG1, washed,
incubated with a biotinylated link antibody (DAKO) and
peroxidase-labeled streptavidin (DAKO). Colour was
developed by using Diaminobenzidine as chromogen.
mRNA extraction and cDNA library construction
Cultured SMMUpos cells (4 × 107) were incubated with
denaturing solution, incubated on ice for 5–10 minutes
and centrifuged at 15,000 × g for 5 minutes at 4°C. After
two rounds of phenol:chloroform extractions 10.0 ml iso-
propanol (Sigma) was added, mixed, incubated on ice for
10 minutes and washed. 0.5 ug total RNA, 100 ul 10×
Dnase buffer I and 5 ul Dnase I (10 units/ul) (Boehringer)
were brought to a volume of 1 ml by adding deionized
Rnase-free water. The reaction mix was incubated at 37°C
for 1 hour, followed by addition of 100 ul 10 × Termina-
tion Mix (1.0 M EDTA, ph 8.0; 1.0 mg/ml Glycogen
(Sigma). 1 volume phenol:chloroform: isoamyl alcohol
(25:24:1) (Biorad) was added, vortexed vigorously and
centrifuged at 12,000 × g for 15 minutes at 4°C. 100 ul of
7.5 M NH4OAC and 1.5 ml 96% ethanol were added, vor-
texed thoroughly and spun at 12,000 × g for 20 minutes.
12.5 mM Tris-HCL (pH 8.3), 18.75 mM KCL, 0.75 mM
MgCl2, 5 mM dNTP (GibcoBRL) were added to 5 ug total
RNA and incubated at 42°C for 2 minutes. 200 units
SUPERSCRIPT II (GibcoBRL) were added, incubated for
further 50 minutes, followed by 70°C for 15 minutes. The
cDNA was unidirectionally inserted into the Uni-ZAP™XR
vector system (Stratagene, Ja Jolla, CA), which is known
for the high efficiency of lambda library construction and
the convenience of white-blue color selection. The inserts
can be in-vivo excised in form of the pBluescript SK(-)
phagemid. The library was synthesized using the ZAP-
cDNA® synthesis method [7]. The library was aliquoted,
DMSO was added to a final concentration of 7% and
stored at -80°C.
Immunoscreening of cDNA library
Amplification and screening of the cDNA were performed
in E. coli XL1-blue host strain. The bacterial cells were
coincubated with the phage and incubated for 15 minutes
at 37°C to allow the phage to absorb to the bacterial cells.
Top agar was added to the mixture, poured onto agar
plates, distributed and incubated at 42°C until small
plaques became visible. Nitrocellulose membranes were
submersed with 10 mM IPTG, dried, applied to the agar
Cytospins with mAb SM5-1 Figure 2
Cytospins with mAb SM5-1. Immunohistochemical stain-
ing (cytospin) of SMMUpos (A) or SMMUneg (B) cells with 
mAb SM5-1.BMC Cancer 2006, 6:8 http://www.biomedcentral.com/1471-2407/6/8
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plates and incubated for 3.5 hours at 37°C. The mem-
branes were washed in TBST, immersed in blocking solu-
tion and incubated with 8 ug/30 ml blocking solution
mAb SM5-1. After washing 0.2 ug/ml Ab-AP conjugate
was added for 1 hour at RT. The membranes were then
immersed in the BCIP (0.3 mg/ml)-NBT (0.15 mg/ml)
(Stratagene) color development solution until positive
reactions were clearly seen. Membranes were aligned and
positive clones plugged from the agar, transferred to 1 ml
of SM buffer with 1 drop of chloroform and incubated at
RT for 1–2 hours. After centrifugation the supernatant was
collected and chloroform added to a final concentration
of 0.3%. XL-1 Blue cells, diluted in 10 mM MgSO4 to an
OD600 = 0.5 were mixed with 300 ul of the picked clones,
incubated for 15 minutes at 37°C, mixed with melted top
agar and plated on 150-mm plates of bottom agar. After
6–8 hours incubation the agar-plates were overlaid with
8–10 ml of SM buffer and stored at 4°C with shaking. On
day three the phage suspension was removed and chloro-
form added to a final concentration of 5%, incubated at
RT and washed.
In vivo excision using the ExAssist/SOLR system
The excision of the cloned fragments was performed
according to the manufacturer's manual (Stratagene).
XL1-Blue cells were co-infected with the phage clones
(containing >1 × 105 phage particles) and helper phage
ExAssist (>1 × 106 pfu/ml) for 15 min at 37°C, followed
by incubation in LB broth for 2–2.5 hours at 37°C with
shaking. The supernatant was heated at 70°C for 15 min-
utes to kill the host cells and release the phagemids. The
cell-phage mixture was centrifuged for 15 minutes at 4000
× g and the supernatant containing phagemids was incu-
bated with E. coli SOLR (OD600 = 1.0) cells to produce
FACS analyses with SM5-1 and Fibronectin antibodies in MAZ and PET cell line Figure 3
FACS analyses with SM5-1 and Fibronectin antibodies in MAZ and PET cell line. Human melanoma cell lines MAZ 
and PET react with mAb SM5-1. MAZ reacts also with fibronectin mAbs TV-15 and FN15 while PET does not.
MAZ PET
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plasmid clones and plated on LB-ampicillin plates for
overnight incubation at 37°C.
DNA sequencing
For automated DNA sequencing (Model 375 DNA
sequence system, APPLIED BIOSYSTEMS) the plasmid
DNA was purified using the QIAprep plasmid preparation
system (QIAgen, Hilden, Germany). The primers used in
the sequencing reaction are listed in Additional file 1. 10
ul product of each sequencing reaction was digested with
10 U EcoR I and 10 U Xho I and run on a 0.8% agarose
gel. The PCR products were mixed with 2 ul 3 M NaAC ph
5.4 and 50 ul 95% ethanol, incubated on ice for 10 min-
utes followed by centrifugation at 14,000 rpm for 30 min-
utes. The pellets were washed with 250 ul of 70% ice cold
ethanol, centrifuged at 14,000 rpm for 10 minutes, air
dried and resuspended with 4 ul loading solution (5:1:1
deionized formamide: 50 mM EDTA: Dextran blue),
heated at 90°C for 2 min, cooled and run on the sequenc-
ing gel at 1600 V, 25 mA, 30 W for at least 10 hours. The
sequencing results were compared with Genbank Entries
(BLAST).
RT-PCR
The following primers were used: human beta actin
(accession number: X00351): 5' primer: AAC CTA ACT
TGC GCA GAA AAC (1209 bp to 1230 bp), 3'primer: TTT
ACA CGA AAG AAC TGC TAT C (1551 bp to 1530 bp);
human fibronectin (accession number: X02761):
5'primer: CTG TTA CTG GTT ACA GAG TAA (4623 bp to
4643 bp), 3'primer: TAG GTC ACC CTG TAC CTG GAA
(4917 bp to 4897 bp). Each PCR reaction was performed
in 10 mM Tris-HCL, ph 8.3, 50 mM KCL, 3 mM MgCl2, 0,2
mM dNTP, 0.4 uM 3'primer, 0.4 um 5'primer, 2.5 units
AmpliTaq Gold and 1 ul of the cDNA, prepared by reverse
transcription. The PCR program used was: 10 min at
94°C, 26 cycles of (30 s at 94°C, 1 min at 51°C, 30 s at
72°C), followed by a final additional extension at 72°C
for 5 min. The products were electrophoresed on a 1.0%
agarose gel.
Western blotting
Cell suspensions of SMMUpos or SMMUneg cells were
lysed in lysis buffer and 50 µg of protein was electro-
phoresed on a 5% polyacrylamide gel in a minigel appa-
ratus (Bio-Rad), the gel was electrotransferred to
nitrocellulose membranes (Schleicher & Schüll), washed
with distilled water for 5 min and blocked for 1 hour
using a blocking solution composed of 2% milk powder
in PBS. After 3 × 10-min washes in PBS/0.05% Tween 20
(Sigma), mAb SM5-1 (0.1 ug/ml) was incubated with the
membrane in blocking solution for 60 min, washed and
incubated with a secondary Ab (peroxidase-conjugated
goat anti-mouse IgG1) (Dianova) at a 1/250 dilution in
blocking solution for one hour. After further 3 × 10-min
washes, the membrane was incubated with the ECL rea-
gent for 2 min and exposed to x-ray film for 90 s. A broad-
range protein standard marker was used for size determi-
nation.
Results
mAb SM 5-1 is reactive with SMMUpos cells and other 
melanoma cell lines, but not with SMMUneg cells
The mAb SM5-1 was generated by subtractive immuniza-
tion of mice with the human primary melanoma cell line
SMMUneg and the human metastatic melanoma cell line
Lymph node metastasis of patient MAZ immunostained with  mAb SM5-1 Figure 5
Lymph node metastasis of patient MAZ immunos-
tained with mAb SM5-1. Immunohistochemical staining of 
a lymph node metastasis of patient MAZ.
Cytospin of cell line MAZ immunostained with mAb SM5-1 Figure 4
Cytospin of cell line MAZ immunostained with mAb 
SM5-1. Immunohistochemical staining (cytospin) of MAZ 
cells with mAb SM5-1.BMC Cancer 2006, 6:8 http://www.biomedcentral.com/1471-2407/6/8
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SMMUpos established from the same patient. Theoreti-
cally, the antigen recognized by SM5-1 should be associ-
ated with the metastatic behavior of the melanoma and
may also only be expressed in metastatic melanoma cell
SMMUpos, but not in primary melanoma cell SMMUneg.
As shown in Fig. 1, upper part (FACS analyses) and Fig. 2
(cytospins), the SMMUpos cell line is strongly positive for
SM5-1, while SMMUneg is not. Therefore, SM5-1 recog-
nizes an antigen which is differentially expressed by the
two cell lines. In order to confirm the reactivity of SM5-1
with other human melanoma tissue, 47 different human
melanoma cell lines were immunostained and analyzed
by FACS. All 47 cell lines were positive for SM5-1. Exam-
ples are shown in Fig. 3, upper part for the cell lines MAZ
and PET as well as for the SM5-1 stained cytospin (Fig. 4)
or lymph node metastasis (Fig. 5) of Patient MAZ. SMMU
pos cells also reacted with the two fibronectin antibodies
TV-1 and FN15 while SMMUneg cells were completely
negative for these antibodies, suggesting a complete loss
of fibronectin in SMMUneg and further suggesting, that
mAb SM5-1 might recognize the same pan-fibronectin
form as TV-1 and FN15 (Fig. 1). TV-1 and FN15 were reac-
tive in only a subset of the 47 melanoma cell lines. One
example is shown in Fig. 3 with absent and present reac-
tivity for the TV-1 and FN15 antibodies in the melanoma
cell line MAZ and PET, respectively.
Sequencing strategy of positively identified clones Figure 6
Sequencing strategy of positively identified clones. The insert was first sequenced by the universal primer T7 (or M13 -
20 primer) in one orientation and by the universal M13 reverse primer in the reverse orientation. Since the range of sequenced 
DNA was short (a few hundred base pairs), a sequence from near the end of this run was used to design a second primer, 
which primed the sequence from this region and moved another few hundred nucleotides further. From the end of this run the 
third primer was designed and the circle was repeated until the entire insert had been covered.
prepare single stranded DNA
Positive cDNA clones pBluescrip SK
sequence DNA using USP
phagemid with the original phagemid with the opposite
cDNA strand (+ ) orientation strand (- )
M13 -20 primer
or T7 M13 rev primer
Design the 2nd primer Design the 2nd primer
Sequence Sequence
Design the 3rd primer Desing the 3rd primer
Sequence Sequence
strand +
strand -
combine the sequence dataBMC Cancer 2006, 6:8 http://www.biomedcentral.com/1471-2407/6/8
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Immunoscreening of SMMUpos human melanoma cDNA 
library with mAb SM5-1
After the initial screening of independent recombinants,
192 putative clones were identified. These clones were
taken through several rounds of purification by replating
and rescreening with mAb SM5-1. After further rounds of
screening, nine clones (clones 127-1a, 130-1, 131-2-2,
139-1, 146-1, 181-2, 184-1, 185, 187-1) recognized by
mAb SM5-1 were confirmed. Several positive plaques
from each clone were picked and re-plated out in a 1:100
dilution of the plasmid (about 30–50 plaques in one 82
mm plate). A single positive clone was further picked and
reamplified by plating out in high concentration on LB-
tetracycline plates. At this point all plaques gave an
equally strong signal and all clones were considered pure
positive ones.
Sequence of the full length of the positive clones
All nine positive clones were completely sequenced (Fig.
6, sequencing strategy) and compared with the Genbank
sequences (BLAST at NCBI). Each primer was designed
based on three criteria: 1) primer length should be 20 bps
2) the GC content should be approximately 50% of the
primer sequence 3) the 3' primer sequence should not be
AT, TA, GC or CG. Two panels of primers were designed,
one for the original strand and one for the reverse strand.
In order to exclude mutations in the sequence, the
sequencing was repeated three times at the same region
Alignment of nine positive clones' fragments Figure 7
Alignment of nine positive clones' fragments. Alignment of nine positive clones' fragments from EcoR I and Xho I diges-
tion and comparison to fibronectin. E0: EcoR I site of polylinker; E1: EcoR I site in fibronectin DNA sequence at position 4150; 
E2: EcoR I site in fibronectin DNA sequence at position 6680; X0: Xho I site of polylinker; X1: Xho I site in fibronectin DNA 
sequence at position 4062; X2: Xho I site in fibronectin DNA sequence at position 4122; X3: Xho I site in fibronectin DNA 
sequence at position 4918. All nine clones overlapped from the poly(A). The shortest clone 184 spanned the sequence from 
the poly(A) end to 4503 bp of fibronectin; the longest clone146 spanned from poly(A) end to 1998 bp of fibronectin.
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FN
X 2 X 3 X 0
E 0 X 1 E 1 E 2
Clone 146
1998 bp X2 X 3 X 0
E 0 X 1 E 1 E 2
Clone 185
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E 0 X 1 E 1 E 2
Clone 127
2319 bp X2 X 3 X 0
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Clone 181/130
2652 bp X2 X 3 X 0
E 0 X 1 E 1 E 2
Clone 187
2838 bp X2 X 3 X 0
E 0 X 1 E 1 E 2
Clone 131
3952 X2 X 3 X 0
E 1 E 2
Clone 139
4179 bp X3 X 0
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Clone 184
4503bp X3 X 0BMC Cancer 2006, 6:8 http://www.biomedcentral.com/1471-2407/6/8
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and the sequenced regions completely overlapped. The
primers (listed in Additional file 1) and the locations of
the primers are shown in the Additional file 2 in bold and
italic sequence. The sequence results showed that all nine
clones were similar to the human cellular fibronectin
mRNA (Accession Number: X02761) and the identity
scores were about 98%. The deduced amino acid
sequences of the positive clones were 100% identical to
the human fibronectin sequence. The sequence of the pos-
itive clones compared with fibronectin pre-mRNA is
shown in Additional file 2. All nine clones overlapped.
The shortest clone, which spanned the segment of
fibronectin from 4503 bp to the poly(A) end, was
sequenced four times in order to be certain that there was
no mutation in this region. The shortest clone included
the ED-A region, but excluded the RGD motif. There was
no ED-B region in any of the clones.
Restriction map of positive cDNA clones
After the nine clones were purified and amplified, the pre-
pared plasmid DNA was digested with EcoR I and Xho I
and electrophoretically separated on a 0.8% agarose gel to
determine if the plasmid with the inserts were successfully
prepared. The alignment of the nine clones based on the
restriction map and the DNA sequencing in shown in Fig.
7.
Sequencing of the IIICS Region
The IIICS region of all nine identified clones was
sequenced. There were two kinds of IIICS splicing variants
present in the nine clones, one is the 120aa type (15 bp to
482 bp) in clone 185 and the other type is the 89aa type
(14 bp to 282 bp) in all other eight positive clones (Addi-
tional file 3).
Expression of ED-A fibronectin at mRNA level in 
SMMUpos and SMMUneg cells
Fibronectins are present in all body fluids and on the cell
surface of most cell types and intercellular matrices. In
order to confirm if the fibronectin recognized by mAb
SM5-1 expressed is the same as the one expressed on the
cellular level, the mRNA expression levels of fibronectins
in SMMUpos und SMMUneg cells were analyzed. Total
mRNA of SMMUpos and SMMUneg was prepared and the
primers were designed in the ED-A region (see material
and methods) according to the human fibronectin
sequence of the positive clones recognized by mAb SM5-
1. Human β-actin mRNA was used as a control. The
SMMUpos cell line expressed both human ED-A fibronec-
tin and human β-actin mRNA, while the SMMUneg cell
line expressed only the human β-actin mRNA (Fig. 8).
Molecular weight of FN reactive with mAb SM 5-1
In order to know the molecular weight of the fibronectin
reactive with the monoclonal antibody SM 5-1, the pro-
teins of SMMUpos and SMMUneg cells were extracted and
the cell lysates run on a 5% polyacrylamide gel, blotted
onto nitrocellulose membrane and immunostained with
mAb SM 5-1. The molecular weight of FN expressed in
SMMUpos is about 200 KDa, which is in line with the
expected molecular weight [8](Fig. 9). SMMUneg cells
were negative, as expected.
Discussion
By screening a cDNA library generated from the metastatic
melanoma cell line SMMUpos, the highly sensitive mon-
oclonal antibody SM5-1 was found to recognize two
Western blotting using mAb SM5-1 Figure 9
Western blotting using mAb SM5-1. Western blotting 
of the protein extracted from the SMMUpos cells with mon-
oclonal antibody SM 5-1. 1: molecular weight standard; 2: 
SMMUpos; 3: SMMUneg.
220 KDa
200 KDa
1 23
RT-PCR of SMMUpos and SMMUneg fibronectin expression Figure 8
RT-PCR of SMMUpos and SMMUneg fibronectin 
expression. RT-PCR of SMMUpos and SMMUneg fibronec-
tin expression using fibronectin primers. Lane 1: PST I DNA 
marker: Lane 2: Fibronectin expression in SMMUpos; Lane 3: 
Fibronectin expression in SMMUneg; Lane 4: β-actin expres-
sion in SMMUpos; Lane 5: β-actin expression in SMMUneg.
12 345
250 bp
300 bpBMC Cancer 2006, 6:8 http://www.biomedcentral.com/1471-2407/6/8
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fibronectin isoforms with the ED-A and CS1 regions.
Fibronectins are high molecule weight adhesive glycopro-
teins present in soluble form in plasma (plasma fibronec-
tin, heterodimeric), other body fluids and in insoluble
form in the extracellular matrix, basal lamina as well as on
cell surface (cellular fibronectin, heterodimers or multim-
ers). Both forms have similar but not identical subunits of
200–280 KDa, which are made up of a series of repeating
units of three types and joined by two disulfide bounds at
their carboxyl terminus [8,9]. Each subunit of plasma and
cellular FN shows considerable heterogeneity in charge
and size which is accounted for by alternative splicing and
variable posttranslational modifications, e.g. glycosyla-
tion, phosphorylation and sulphation [10,11]. The
fibronectin variant epitope recognized by mAb SM5-1 has
also to be posttranslationally modified since some of the
melanoma cell lines examined do not express the stand-
ard fibronectin form, but do express a FN form recognized
by SM5-1, suggesting that a melanoma-associated variant
with posttranslational modification is widely expressed in
melanoma. Each polypeptide subunit of FN is composed
of type I, type II, and type III homology repeats containing
specific sites for binding to cells and a range of molecules,
including collagen, fibrils, and heparin [12-14]. Alterna-
tive splicing is seen within the central run of type III
repeats. ED-A and ED-B can be included or excluded from
FN mRNA by Exon skipping [8,15-18]. A third nonho-
mologous region called V (for variable) or IIICS (type III
connecting segment) can be subdivided in humans in the
5' V25 segment and the 3' V31 segment being spliced
independently of the central 64 amino acids to produce 5
potential variants [15,19]. Borsi et al. have demonstrated
that FNs from transformed or tumor derived cells are com-
posed of a population of molecules in which both the
IIICS and ED-A sequences are expressed more than in FNs
from normal cells [20].
The multiple functions of fibronectin include the estab-
lishment and maintenance of normal cell morphology,
promotion of cell migration and enhancement of cell
attachment, onto- and oncogenic transformation [21-26].
The functional role of fibronectin in relation to the bio-
logical behavior of the melanoma is open to speculation
but functionally active integrin alpha(5) and fibronectin
seems to be instrumental in melanoma metastases [27].
Certain short peptide sequences in fibronectin, such as
RGD peptide in the type III domain, the LDV sequence in
the CS1 region, the REDV peptide sequence in the CS5
region produced by the alternative splicing of the IIICS
region of the fibronectin and the peptides I and II in the
heparin -binding domain of the fibronectin contribute to
the process of tumor cell adhesion and migration [28-34].
In the immunoscreening with mAb SM5-1 the mAb recog-
nized two fibronectin isoforms without ED-B region in
any of the nine clones, but the shortest clone, which
spanned the sequence of fibronectin from 4503 bp to the
3' end, included the ED-A region. It was reported that in
metastatic melanoma, only ED-A fibronectin was found,
but no ED-B fibronectin [35]. This finding is consistent
with our results of the RT-PCR experiment (Fig. 8). Xia et
al. showed that the ED-A region increases the adhesive
properties of fibronectin [36]. Therefore, one likely expla-
nation for the in vivo effects of ED-A fibronectin on
metastasis is that cells expressing high levels of ED-A
fibronectin in the primary tumor will display a greater
degree of homotypic adhesion in the primary melanoma
and consequently fewer melanoma cells will exit the pri-
mary site and circulate to other tissues. Full length recom-
binant FNs including ED-A are incorporated into
pericellular matrices more effectively than forms lacking
ED-A [37]. Early work on fibronectin showed that
fibronectin is deposited into the extracellular matrix of
normal cells but that malignant counterparts of such cells
often failed to deposit a fibronectin matrix [38,39].
The make-up of the different FN isoforms depends on the
FN source and the alternative splicing of the FN pre-
mRNA is regulated in a cell-, tissue-, and development-
specific manner [17,40-45]. Alternative splicing may rep-
resent an important flexible mechanism and be able to
generate diversity in a reversible fashion in response to
developmental and environmental cues without requiring
the expression of new genes. The FN containing ED-A seg-
ment is expressed 10 times higher in the tissue culture
medium of tumor derived or SV-40 transformed human
cells than that from normal human fibroblasts [20]. It was
suggested that for some cell types regulation of the adhe-
sion-promoting activity of FN may occur by alternative
RNA splicing in the IIICS region [46]. The sequence of the
minimal cell recognition site in the "cell-binding"
domain of fibronectin has been identified as the tetrapep-
tide Arg-Gly-Asp-Ser (RGDS) [47,48]. The peptide RGDS
and related short RGD-containing peptides have been
found to inhibit both cell adhesion to fibronectin in vitro
and experimental metastasis in vivo, also in a melanoma
model [46,49,50]. The RGD motif was not included in
our sequence but there are two other attachment sites, one
is the REDV, which is somehow related to RGDS, present
in the IIICS region and designed by Humphries's group as
CS5 peptide and the another one is the EILDVPST peptide
or CS1. It was shown that the CS1 peptide of fibronectin,
lacking the RGD motif, actively inhibited tumor metasta-
sis in spontaneous and experimental metastasis models
[50].
The IIICS region is one of the alternative splicing regions
that generate multiple fibronectin mRNAs. This region
corresponds to the non-homologous segment which con-
nects the last two type III units at the C-terminal end of theBMC Cancer 2006, 6:8 http://www.biomedcentral.com/1471-2407/6/8
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protein (IIICS). Fibronectin cDNAs differ by the presence
or absence of IIICS segments of 285 bps or 360 bps,
encoding 95 or 120 amino acids, respectively [18]. There
are however five types of alternative splicing in the IIICS
region, two of them (120aa type and 89aa type) include
the CS1 peptide and both of which were found. Clone 185
has the 120aa type of the alternative splicing of the IIICS
and the other eight clones have the 89aa type of the IIICS
alternative splicing. Competitive inhibition assays and
avidity determinations suggested that the CS1 region may
be the major site of interaction with the melanoma cell
surface [46,51].
In malignant cells, the matrix deposition is disturbed and
fibronectin is absent from the matrix of many tumorigenic
cell lines [47]. Three events appear to be important: the
binding of fibronectin to cell surface receptors, the bind-
ing between individual fibronectin molecules and cross-
linking between fibronectin molecules [52,53]. The
malignant cells are incapable of depositing a fibronectin
matrix but still adhere almost normally to fibronectin.
Moreover, they produce fibronectin that is unaltered in
the sense that normal cells can incorporate it into their
matrix [26]. To these paradoxical observations there is still
no sound explanation. It is also reported that the addition
of exogenous fibronectin restores the fibronectin matrix
and cytoskeletal organization in cultures of cells that are
incapable of assembling a matrix when cultured in a nor-
mal medium [53,54]. For metastatic melanoma cells,
presence of ED-A and CS1 may give them the ability to be
quickly arrested in the vasculature at secondary sites and
pass through the surrounding tissue. The adhesive mole-
cules act independently or in concert to direct melanoma
cells to particular tissue and grow at the secondary site.
The metastases are then established.
Conclusion
The mAb SM5-1 does not recognize a metastases-associ-
ated antigen as originally thought but react with a signifi-
cantly higher percentage of melanoma specimens than
any other melanoma associated antibody. The epitope
recognized by mAb SM5-1 is a melanoma-associated
fibronectin variant. More detailed analyses of possible
post-translational modifications and functional studies
are indicated on this epitope which is possibly involved in
metastatic spread. ED-B FN can be used as a target for
immunotherapy and antibodies to ED-B can be used both
diagnostically or therapeutically in various malignancies
[55,56]. It seems therefore to be feasible to potentially use
the ED-A variant recognized by mAb SM5-1 for the same
purposes.
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